Immunogenic and Protective Response in Mice Immunized with a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype Made in Fetal Rhesus Lung Cells

View More View Less
  • Department of Virus Diseases, Walter Reed Army Institute of Research, Microbix Biosystems Inc., United States Food and Drug Administration, Office of Device Evaluation, Washington, District of Columbia, Canada

The feasibility of a purified, inactivated vaccine (PIV) against dengue type 2 (DEN-2) virus was explored. Dengue-2 virus strain 16681 was used for producing a monotypic PIV. Virus adapted to fetal rhesus lung (FRhL-2) cells was harvested from roller bottle culture supernatant fluids, concentrated, and purified on sucrose gradients. Analysis of purified virus preparations by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting showed primarily envelope (E) and premembrane (prM) antigens. These preparations had a purity, estimated from silver-stained gels, of approximately 70%, and a yield, based on recovery of virus and viral antigen, of 10–20%. The purified virus was inactivated with 0.05% formalin at 22°C, or alternatively, with 7 mRads from a 60Co source. Vaccinated mice developed high titers of anti-DEN-2 virus neutralizing antibody and were partially protected from virus challenge. These results warrant further testing and development of PIVs for the other DEN virus serotypes.